Table IV.
In vivo activities of zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin against mice infected with MRSA S19 clinical isolate.
| Microorganism inoculum (CFU/mouse) | Antimicrobial agenta | MIC (μg/ml) | Count in dissected lungs log10 (CFU/ml)b | ED50c (mg/kg) |
|---|---|---|---|---|
| Methicillin-resistant S. aureus clinical isolate S19 | Zabofloxacin | 0.06 | 3.66 | 29.05 |
| Moxifloxacin | 0.06 | 4.31 | 38.69 | |
| Levofloxacin | 8 | 4.01 | > 40.00 | |
| Ciprofloxacin | 16 | 4.24 | > 40.00 |
a
Each antimicrobial agent was administrated twice orally at 1 and 4 h post infection.
b
Count in control group receiving saline was log10 5.5 CFU/ml.
c
ED50: median effective dose needed to protect 50% of the mice.